Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma
Qi Chang, Jiayi Li, Yue Deng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2466-2486
Closed Access | Times Cited: 12

Showing 12 citing articles:

Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
Xin Wu, Xin Zhang, Shaoshan Tang, et al.
Cell Biology and Toxicology (2025) Vol. 41, Iss. 1
Open Access
Progress in ubiquitination and hepatocellular carcinoma: a bibliometric analysis
Ming Li, Zhiliang Xu, Shanhui Liang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
P300 regulates Melanophilin expression by modulating TFAP2A binding through histone acetylation
Chan Song Jo, Zhao Hairu, Gyu Cheol Baek, et al.
Journal of Dermatological Science (2025)
Closed Access
Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity
Praveen Kumar Tiwari, Sai Reddy Doda, Raghu Vannam, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129676-129676
Closed Access | Times Cited: 2
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher McNair, Lakshmi Ravindranath, et al.
Oncogene (2024)
Open Access | Times Cited: 1
Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer
Mengjun Ma, Mengyao Li, Chengwei Zhang, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher McNair, Lakshmi Ravindranath, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Discovery of an EP300 Inhibitor using Structure-based Virtual Screening and Bioactivity Evaluation
Dabo Pan, Yaxuan Huang, Dewen Jiang, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 25, pp. 1985-1994
Open Access
Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity
Iván Cheng‐Sánchez, Katherine Gosselé, Leonardo Palaferri, et al.
JACS Au (2024) Vol. 4, Iss. 9, pp. 3466-3474
Open Access
Progress in ubiquitination and hepatocellular carcinoma: A bibliometric analysis
Ming Li, Zhiliang Xu, Shanhui Liang, et al.
Research Square (Research Square) (2024)
Closed Access
Dysregulation of the p300/CBP histone acetyltransferases in human cancer
Longxia Xu, Hongwen Xuan, Xiaobing Shi
Epigenomics (2024) Vol. 17, Iss. 3, pp. 193-208
Closed Access
Page 1

Scroll to top